Reminyl, Galantamine
Reminyl, Galantamine Newswire

Reminyl, Galantamine Newswire

Comprehensive Real-Time News Feed for Reminyl, Galantamine (generic).

Results 1 - 20 of 20 in Reminyl, Galantamine (generic)

  1. Gateway to InfinityRead the original story w/Photo

    Sep 3, 2015 | The Huffington Post

    Dreaming has long been considered a gateway to the infinite. The ancient Greeks believed dreams predicted the future.


  2. Much ado about cognitive declineRead the original story

    Aug 25, 2015 | Times Beacon Record

    I think most of us can agree that we want to age as gracefully as possible. But, what does this mean? While we may want to avoid physical ailments, such as achy joints and musculoskeletal pain, cognitive decline seems to be one of the scarier prospects as we age.


  3. Positive allosteric modulation of alpha 7 nicotinic acetylcholine...Read the original story

    Aug 23, 2015 | CiteULike

    A wide body of preclinical and clinical data suggests that alpha 7 nicotinic acetylcholine receptors may represent useful targets for cognitive improvement in schizophrenia and Alzheimer 3s disease. A promising recent approach is based on the use of positive allosteric modulators of I 7-nAChRs due to their several advantages over the direct agonists.


  4. Current Practices in the Treatment of Alzheimer Disease: Where is the ...Read the original story

    Aug 18, 2015 | CiteULike

    The purpose of this systematic review was to review the current place in therapy of the 4 medications, donepezil, rivastigmine, galantamine, and memantine, approved for the treatment of Alzheimer disease since the publication of Phase III trials. A systematic literature search of MEDLINE and EMBASE was conducted for articles published in the past 10 years.


  5. Testing for early signs of Alzheimer just got easierRead the original story w/Photo

    Aug 11, 2015 |

    Patients will soon be able to conduct a simple test to determine whether they are suffering from early onset Alzheimer's while their physicians are busy with other patients, using a cognitive assessment tool called Conivue that works something like a video game. According to inventor, Charles Duffy, a neurology professor at the University of Rochester, NY, the device can detect subtle lapses in the perceptual ability of the brain that may signal the early development of the disease in as little as 10-minutes.


  6. Dementia Meds Tied to Harmful Weight LossRead the original story w/Photo

    Aug 3, 2015 | News Max

    Common dementia medications can cause harmful weight loss in some patients, new research shows. The findings, by University of California-San Francisco scientists, underscore the need for clinicians take into account for the risks - as well as the potential benefits - of prescribing such drugs to older adults.


  7. Common Dementia Drugs Might Do More Harm Than GoodRead the original story w/Photo

    Aug 3, 2015 | MSN Healthy Living

    Researchers from the University of California-San Francisco are finding that commonly prescribed dementia medications can lead to dangerous weight loss in patients . In light of this new evidence, they are cautioning physicians to be careful when prescribing medication to their patients.


  8. Common medications for dementia could cause harmful weight lossRead the original story w/Photo

    Aug 3, 2015 | PhysOrg Weblog

    Medications commonly used to treat dementia could result in harmful weight loss, according to UC San Francisco researchers, and clinicians need to account for this risk when prescribing these drugs to older adults, they said. "This is very relevant to patient care because unintentional weight loss in older adults is associated with many adverse outcomes, including increased rates of institutionalization and mortality, a decline in functional status, and poorer quality of life," said lead author Meera Sheffrin, MD, geriatrics fellow in the UCSF School of Medicine at the UCSF-affiliated San Francisco VA Medical Center.


  9. Common Dementia And Alzheimer's Medications May Cause...Read the original story w/Photo

    Aug 3, 2015 | Medical Daily

    Researchers from the University of California-San Francisco are finding that commonly prescribed dementia medications can lead to dangerous weight loss in patients . In light of this new evidence, they are cautioning physicians to be careful when prescribing medication to their patients.


  10. Positive allosteric modulators of alpha 7 nicotinic acetylcholine...Read the original story

    Aug 2, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Alpha 7 nicotinic acetylcholine receptors have generated great interest as targets of new pharmacological treatments for cognitive dysfunction in schizophrenia.


  11. Dream Hacking: Understanding Everyday Behaviors That Impact Your DreamsRead the original story w/Photo

    Jul 24, 2015 | The Huffington Post

    No, we aren't talking about Inception or the latest sci-fi thriller; what you do while awake actually can influence your dreams and how you sleep! However, newer research shows that some behaviors can actually affect your dreams in both good and bad ways. Learn what habits and daytime activities might be influencing your rest, and see how to hack your dreams.


  12. New Alzheimer's drug could slow decline: expertsRead the original story w/Photo

    Jul 22, 2015 | ABC News

    "In other words, for individual patients... they don't get better than they were when they started the drug but it slows the rate of decline." Eli Lilly said patients with mild Alzheimer's disease who took the experimental drug early in the course of their disease preserved more of their cognitive and functional ability.


  13. Cerespir Submits Special Protocol Assessment Request To FDA For A...Read the original story

    Jun 30, 2015 | BioSpace

    CereSpirTM Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has submitted a Special Protocol Assessment request to the U.S. Food and Drug Administration to initiate detailed design discussions for a Phase 3 clinical study of CSP-1103 to test its ability to slow the Progression of Mild Cognitive Impairment due to Alzheimer's Disease . The SPA request includes the proposed Phase III study protocol, statistical analysis plans and briefing materials along with specific questions from CereSpir to facilitate a meaningful dialogue with the FDA on the proposed study design.


  14. More evidence needed for chronic fatigue diagnosis, treatmentsRead the original story w/Photo

    Jun 17, 2015 | PhysOrg Weblog

    Criteria for diagnosing myalgic encephalomyelitis/chronic fatigue syndrome as well as treatment options are addressed in two systematic evidence reviews published in the June 16 issue of the Annals of Internal Medicine . Elizabeth Haney, M.D., from the Oregon Health & Science University and Providence Cancer Center in Portland, and colleagues reviewed methods to diagnose ME/CFS in adults.


  15. Upcoming Events: A Dosing Decision For BioMarin, Plus Roche To Get Alzheimer's DataRead the original story w/Photo

    May 23, 2015 | Seeking Alpha

    Welcome to your weekly digest of approaching regulatory and clinical readouts. Data from BioMarin's Phase II trial of the achondroplasia project BMN 111, expected this month or next, will allow the company to decide whether to test a higher dose.


  16. Antidementia drug treatment in dementia networks in Germany: use...Read the original story

    May 22, 2015 | BioMed Central

    German Center for Neurodegenerative Diseases , Research Group "Interventional Health Care Research", Site Rostock/ Greifswald, Ellernholzstr. 1-2, Greifswald D-17487, Germany Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, Ernst-Moritz-Arndt-University Greifswald, Ellernholzstrasse 1-2, Greifswald D-17487, Germany Background Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment.


  17. The influence of cholinesterase inhibitor therapy for dementia on...Read the original story

    Apr 27, 2015 | BioMed Central

    Division of Geriatric Medicine, Department of Medicine, University of Ottawa, The Ottawa Hospital, 1053 Carling Avenue, Ottawa K1Y 4E9, Ontario, Canada Department of Epidemiology & Community Medicine, University of Ottawa; Ottawa Hospital Research Institute; ICES uOttawa, The Ottawa Hospital, ASB1-003, 1053 Carling Avenue, Ottawa K1Y 4E9, Ontario, Canada Background Cholinesterase inhibitors are used to treat the symptoms of dementia and can theoretically cause bradycardia. Previous studies suggest that patients taking these medications have an increased risk of undergoing pacemaker insertion.


  18. Effective Drug Therapy for Alzheimer's Disease Remains ElusiveRead the original story

    Mar 13, 2015 | ASHP

    In the two years since the United States set a national goal of effectively preventing or treating Alzheimer's disease by 2025, no new therapies have been approved, and recent clinical trials of investigational drugs have proved disappointing. According to the Pharmaceutical Research and Manufacturers of America, about 83% of drugs that are tested in clinical trials never earn FDA approval.


  19. memantine, Namenda, Namenda XRRead the original story w/Photo

    Feb 24, 2015 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.


  20. AB Science : Successful Completion Of Futility Test For Masitinib In Alzheimer's DiseaseRead the original story

    Feb 9, 2015 | BioSpace

    AB Science SA , a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors , today announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer's disease. Based on these results, the Independent Data Safety Monitoring Committee has recommended the continuation of the study.